Literature DB >> 27338825

Evidence-based Chinese medicine clinical practice guideline for stomach pain in Hong Kong.

Linda L D Zhong1,2, Nan-Nan Shi1,3, Liang Dai1,2, Tat Chi Ziea4, Bacon Ng4, Xu-Dong Tang5, Zhao-Xiang Bian1,2, Ai-Ping Lu6,7.   

Abstract

Stomach pain in Chinese medicine (CM) is a very common disorder in clinical practice and it has been listed as one of the pilot three conditions in Hong Kong to develop evidence-based CM clinical practice guidelines (CM CPGs). The aim of this stomach Pain CPG is to summarize the treatment methods of stomach pain with CM and evaluate reasonably, then to guide local licensed CM practitioners and provide beneficial reference for social medical decision makers and patients. In this manuscript, we defined stomach pain in CM and the category of chronic gastritis in Western medicine. The clinical manifestation, CM pattern classification, and CM intervention including herbal medicine treatment based on pattern differentiation, symptomatic treatment, acupuncture treatment, regulation and nursing were illustrated.

Entities:  

Keywords:  Chinese herbal medicine; Chinese medicine pattern; clinical practice guideline; stomach pain

Mesh:

Substances:

Year:  2016        PMID: 27338825     DOI: 10.1007/s11655-016-2586-y

Source DB:  PubMed          Journal:  Chin J Integr Med        ISSN: 1672-0415            Impact factor:   1.978


  1 in total

1.  Enhanced evidence-based chinese medicine clinical practice guidelines in Hong Kong: a study protocol for three common diseases.

Authors:  Nannan Shi; Linda L D Zhong; XueJie Han; Tat Chi Ziea; Bacon Ng; Zhaoxiang Bian; Aiping Lu
Journal:  Evid Based Complement Alternat Med       Date:  2015-03-01       Impact factor: 2.629

  1 in total
  1 in total

1.  A national survey of Chinese medicine doctors and clinical practice guidelines in China.

Authors:  Mengyu Liu; Chi Zhang; Qinglin Zha; Wei Yang; Ya Yuwen; Linda Zhong; Zhaoxiang Bian; Xuejie Han; Aiping Lu
Journal:  BMC Complement Altern Med       Date:  2017-09-06       Impact factor: 3.659

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.